Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
2019-003139-47Phase 3Active
- Sponsor
- Sanofi
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab in smoldering multiple myeloma (SMM) (3 arms), sponsored by Sanofi. Primary endpoint: Safety assessment: adverse events. Started Jan 2020; status: active.
02
Drugs
isatuximab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2019-003139-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003139-47.